Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 57, Issue 8

Issues

Fasting serum bile acids concentration is associated with insulin resistance independently of diabetes status

Sang-Guk Lee
  • Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yong-ho Lee
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eunhye Choi
  • Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yonggeun Cho
  • Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jeong-Ho Kim
  • Corresponding author
  • Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-04-09 | DOI: https://doi.org/10.1515/cclm-2018-0741

Abstract

Background

Bile acids (BAs) have been demonstrated to exert a variety of metabolic effects and alterations in BAs have been reported in patients with obesity, insulin resistance (IR) and type 2 diabetes mellitus (T2DM). However, it is unclear which metabolic condition is the main contributor to alterations in BAs. In this study, we investigate the associations between different BA profiles with glycemia, obesity or IR status.

Methods

Fasting serum concentrations of 15 BA species were determined in a total of 241 individuals (71 drug-naïve patients with T2DM, 95 patients with impaired fasting glucose [IFG], and 75 healthy controls.

Results

A comparison of the mean values of the BAs revealed no significant differences between normoglycemic controls and patients with IFG or T2DM. However, when the entire cohort was divided according to the presence of IR as determined by a homeostasis model assessment of insulin resistance (HOMA-IR) value >2.5, the levels of total BA and most species of BAs were significantly higher in patients with IR than in patients without. In the correlation analysis, most species of BAs, as well as total BA, were significantly associated with HOMA-IR levels. Furthermore, when the subjects were divided into four groups according to IR and diabetic status, subjects with IR had significantly higher total BAs than participants without IR both in diabetic and non-diabetic groups. Ultimately, multiple linear regression analysis identified HOMA-IR as the only significant contributor to most serum BA species.

Conclusions

Our findings support the essential role of IR in regulating BA metabolism and that this effect is independent of diabetic status.

This article offers supplementary material which is provided at the end of the article.

Keywords: bile acids profile; GLP-1; insulin resistance; obesity; type 2 diabetes mellitus

References

  • 1.

    Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap – bile acids in metabolic control. Nat Rev Endocrinol 2014;10:488–98.Web of SciencePubMedCrossrefGoogle Scholar

  • 2.

    Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 2017;152:1679–94.e3.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 3.

    Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909–21.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 4.

    Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60:3318–28.CrossrefWeb of SciencePubMedGoogle Scholar

  • 5.

    Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol 2014;171:R47–65.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 6.

    Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–91.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 7.

    Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365–8.CrossrefPubMedGoogle Scholar

  • 8.

    Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435–40.CrossrefGoogle Scholar

  • 9.

    Wewalka M, Patti ME, Barbato C, Houten SM, Goldfine AB. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 2014;99:1442–51.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 10.

    Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 2013;62:4184–91.PubMedCrossrefGoogle Scholar

  • 11.

    Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 2011;6:e25006.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 12.

    Cariou B, Chetiveaux M, Zair Y, Pouteau E, Disse E, Guyomarc’h-Delasalle B, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab (Lond) 2011;8:48.CrossrefPubMedGoogle Scholar

  • 13.

    Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010;52:1455–64.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 14.

    Sun W, Zhang D, Wang Z, Sun J, Xu B, Chen Y, et al. Insulin resistance is associated with total bile acid level in type 2 diabetic and nondiabetic population: a cross-sectional study. Medicine (Baltimore) 2016;95:e2778.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 15.

    Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsboll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab 2016;101:3002–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 16.

    American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S8–16.Google Scholar

  • 17.

    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.PubMedCrossrefGoogle Scholar

  • 18.

    World Health Organization Western Pacific Region IAftSoO. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia, 2000:15–21.Google Scholar

  • 19.

    Yamada C, Mitsuhashi T, Hiratsuka N, Inabe F, Araida N, Takahashi E. Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population. J Diabetes Investig 2011;2:373–6.Web of ScienceCrossrefGoogle Scholar

  • 20.

    Marksteiner J, Blasko I, Kemmler G, Koal T, Humpel C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease. Metabolomics 2018;14:1.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 21.

    Pham HT, Arnhard K, Asad YJ, Deng L, Felder TK, Williams LS, et al. Inter-laboratory robustness of next-generation bile acid study in mice and humans: international ring trial involving 12 laboratories. J Appl Lab Med 2016;1:129–42.CrossrefGoogle Scholar

  • 22.

    Vincent RP, Omar S, Ghozlan S, Taylor DR, Cross G, Sherwood RA, et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem 2013;50:360–4.Web of SciencePubMedCrossrefGoogle Scholar

  • 23.

    Legry V, Francque S, Haas JT, Verrijken A, Caron S, Chavez-Talavera O, et al. Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects. J Clin Endocrinol Metab 2017;102:3783–94.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 24.

    Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem 2012;287:1861–73.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 25.

    Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001;108:1359–67.CrossrefPubMedGoogle Scholar

  • 26.

    Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang JY. Insulin regulation of cholesterol 7 alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. J Biol Chem 2006;281:28745–54.CrossrefPubMedGoogle Scholar

  • 27.

    Li T, Chanda D, Zhang Y, Choi HS, Chiang JY. Glucose stimulates cholesterol 7 alpha-hydroxylase gene transcription in human hepatocytes. J Lipid Res 2010;51:832–42.Web of ScienceCrossrefPubMedGoogle Scholar

  • 28.

    Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA 2008;105:13580–5.Web of ScienceCrossrefGoogle Scholar

  • 29.

    Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470–81.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 30.

    Prinz P, Hofmann T, Ahnis A, Elbelt U, Goebel-Stengel M, Klapp BF, et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci 2015;9:199.Web of SciencePubMedGoogle Scholar

About the article

Corresponding author: Jeong-Ho Kim, MD, PhD, Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea, Phone: +82-2-2228-2448, Fax: +82-2-313-0956


Received: 2018-07-16

Accepted: 2018-12-20

Published Online: 2019-04-09

Published in Print: 2019-07-26


Author contributions: S-G. L. designed the study, analyzed all data and wrote the manuscript. Y. L. recruited the patients and contributed critical discussions. E. C. performed experiments and researched the data. Y. C. contributed critical discussions and produced the illustrations. J-H. K. researched data, contributed statistical analysis and edited the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Ministry of Science, ICT and Future Planning, Republic of Korea (NRF-2017R1C1B5015044) and the faculty research grant of Yonsei University College of Medicine (6-2017-0051).

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organizations played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 8, Pages 1218–1228, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-0741.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in